Company Overview
Kezar Life Sciences, Inc. operates as a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics aimed at addressing unmet medical needs in immune-mediated diseases within the United States. This positioning places the firm squarely within the Healthcare sector and the Biotechnology industry, sectors characterized by high innovation potential but also significant regulatory and development risks. The company currently maintains a market capitalization of $45.40M and employs 55 individuals to advance its research pipeline. These valuation and operational metrics indicate a micro-cap entity that is still in a pre-commercialization phase, where revenue figures are not yet materialized, reflecting the typical financial profile of firms focused on bringing specialized drugs to market rather than generating immediate cash flow.
Financial Health
The company reports no annual revenue and a net income of $-61,705,000 over the trailing twelve months, resulting in an EBITDA of $-64,521,000. The substantial gap between zero revenue and a negative net income reveals a cost structure dominated by research and development expenses, which is standard for clinical-stage biotechnology firms but precludes profitability. Free cash flow stands at $-34,606,752, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which mathematically reflects the absence of revenue and the resulting inability to calculate a positive percentage return on sales. On the liability side, the company holds $90.22M in cash against $9.91M in debt, creating a net cash position that suggests a conservative balance sheet relative to its obligations. The debt-to-equity ratio is 11.95, a figure that appears high on the surface but must be interpreted in the context of a cash-rich, pre-revenue balance sheet where equity value is driven by market capitalization rather than book assets. The current ratio is 7.07, signaling strong short-term liquidity as the company possesses ample current assets to cover its current liabilities many times over. Return on Equity is -56.9% and Return on Assets is -31.3%, metrics that indicate management is currently utilizing the company's capital base to generate losses rather than profits, a normal characteristic of early-stage development but one that signals negative financial performance in the traditional sense.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the absence of earnings, while the Forward P/E is -2.01, a negative figure that implies the market is pricing in anticipated losses or that the stock price exceeds the magnitude of expected negative earnings. The Price to Book ratio is 0.55, indicating that the market is valuing the company at 55 cents on the dollar relative to its book value, which often suggests the market is discounting the asset value or that the company is priced below its tangible net assets. The Price to Sales ratio is N/A because there is no revenue, and the EV/EBITDA stands at 0.54, a valuation metric that can be misleading for pre-revenue companies but here reflects a market cap that is less than half the magnitude of its negative EBITDA. The 52-week high is $7.45 and the 52-week low is $3.53, meaning the stock has experienced significant volatility within this specific trading range over the last year. The Beta value is 0.51, which indicates that the stock's price volatility is less than 50% of the broader market's movement, suggesting lower systematic risk compared to the general market index despite the company's high-risk biotechnology business model.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, as the company has not yet generated positive revenue streams to calculate year-over-year growth rates. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings are theoretically reinvested into the business or consumed by operational losses rather than distributed to shareholders. The overall growth and income profile is characterized by a total lack of financial metrics typically associated with mature businesses, including positive revenue growth, earnings expansion, or dividend distribution, leaving investors with a binary exposure to the success of future clinical trials. This profile implies that the primary value driver is the potential future success of the product candidate zetomipzomib (KZR-616) rather than current financial performance or income generation.